The search for an elusive uniform strategy for a heterogeneous disease: Lesson learned?

Journal of Clinical Oncology

Volumn 31, Issue 14, 2013, Pages 1707-1708

  Seidman, Andrew D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; FULVESTRANT; GAMMA UROGASTRONE; GEMCITABINE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ALOPECIA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; EDITORIAL; FATIGUE; FLU LIKE SYNDROME; HORMONAL THERAPY; HUMAN; MAINTENANCE CHEMOTHERAPY; META ANALYSIS (TOPIC); MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY; TREATMENT DURATION; BREAST TUMOR; FEMALE; NOTE; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY;

EID: 84879473732     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.6894     Document Type: Editorial

References (16)

1. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
2. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor 2-receptor positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
3. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
4. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
5. Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011
6. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3229-3247, 2010
7. Albain KS, Nag SM, Calderillo-Ruiz G, et al: Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26:3950-3957, 2008
8. Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every 3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649, 2008
9. Gennari A, Stockler M, Puntoni M, et al: Duration of chemotherapy for metastatic breast cancer: A systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 29:2144-2149, 2011
10. Seidman AD: How long is long enough? J Clin Oncol 29:2129-2130, 2011
11. Park YH, Jung KH, Im S-A, et al: Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel (KCSG-BR07-02) as first-line chemotherapy. J Clin Oncol 31:1732-1739, 2013
12. Modi S, Seidman AD: Single-agent gemcitabine in the treatment of advanced breast cancer. Clin Breast Cancer 4:S101-S106, 2004 (suppl 3)
13. Modi S, Currie VE, Seidman AD, et al: A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer 6:55-60, 2005
14. Gennari A, Amadori D, De Lena M, et al: Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24:3912-3918, 2006
15. Seidman AD, Brufsky A, Ansari RH, et al: Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Ann Oncol 22:1094-1101, 2011
16. Matsuyama R, Reddy S, Smith TJ: Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490-3496, 2006